Diffuse midline glioma (DMG) is an aggressive brain tumor that grows in the central structures of the brain or spinal cord. It is classified as the highest grade (grade 4) by the World Health Organization, regardless of how the tissue looks under a microscope. DMGs most commonly affect children, but they also occur in adults, with a typical adult diagnosis around age 30.
Where DMG Grows
The “midline” in the name refers to the structures running along the center of the brain and spinal cord. DMGs most often form in the thalamus (a relay station deep in the brain), the pons (a critical part of the brainstem), the spinal cord, and the cerebellum. Because these areas control fundamental functions like movement, balance, breathing, and sensation, tumors here cause serious neurological problems even when they are small.
One well-known subtype, diffuse intrinsic pontine glioma (DIPG), grows specifically in the pons. DIPG has historically been the most recognized form of this disease, especially in children. Under the current classification system, DIPG is now grouped under the broader DMG category when it carries the defining molecular changes.
What Makes DMG Molecularly Distinct
DMG is defined not just by where it grows but by specific changes in its DNA. The most common is a mutation called H3 K27M, found in roughly 80% of DIPGs. This mutation affects a histone protein, which is part of the packaging system that controls how genes are turned on and off. When the packaging goes wrong, cells grow without the normal checks.
In 2016, the WHO created a formal diagnostic category for tumors with this mutation. The 2021 update broadened the definition further, renaming it “H3 K27-altered” to capture additional molecular pathways that produce the same downstream effect, even without the classic H3 K27M mutation. This means a tumor can qualify as DMG through several different molecular routes, all of which disrupt the same gene-regulation machinery.
Among children with the H3 K27M mutation, about 70% carry it in a gene called H3.3 and 30% in a gene producing the H3.1 variant. In adults, genomic profiling consistently finds only the H3.3 variant, with the H3.1 mutation essentially absent. This molecular difference between pediatric and adult cases may influence how the tumors behave and respond to treatment.
Symptoms by Tumor Location
Symptoms depend heavily on where in the midline the tumor sits. Pontine (brainstem) tumors often cause a classic triad: double vision, difficulty with coordination, and weakness on one side of the face or body. These symptoms can appear over just a few weeks. Thalamic tumors may cause headaches, personality changes, weakness on one side of the body, and problems with vision. Spinal cord tumors typically present with back pain, limb weakness, or sensory changes like numbness or tingling.
Signs of increased pressure inside the skull, including headaches, nausea, and vomiting, are common across all locations. About half of patients show signs of damage to the nerve pathways controlling movement (pyramidal tract injury), which can mean progressive difficulty walking or using one hand. Because these symptoms can develop rapidly, the time from first symptom to diagnosis is often short.
How DMG Is Diagnosed
MRI is the primary imaging tool. DMGs typically appear as bright areas on a specific MRI sequence called T2-weighted imaging, reflecting the water content and swelling within the tumor. The enhancement pattern after contrast dye is injected varies. Some tumors show ring-like enhancement, while others enhance minimally or not at all. In pontine tumors, MRI findings are often so characteristic that a biopsy has historically not been required to make the diagnosis, though molecular confirmation is increasingly standard.
When a biopsy is performed, pathologists test for the H3 K27 alteration to confirm the diagnosis. This molecular confirmation is important because it determines eligibility for newer targeted treatments and clinical trials. Tumors in the thalamus or spinal cord are more likely to be biopsied than pontine tumors, where surgery carries higher risks.
Standard Treatment
Radiation therapy is the backbone of DMG treatment and the only standard intervention shown to reliably reduce symptoms and extend life. A typical course delivers focused radiation to the tumor area over about six weeks. Most patients experience meaningful improvement in their neurological symptoms during or shortly after radiation, though this benefit is temporary. The tumor almost always begins growing again within months.
Traditional chemotherapy has been largely ineffective against DMG. Decades of clinical trials testing various drug combinations alongside radiation have failed to show a survival benefit over radiation alone. One major reason is the blood-brain barrier, which prevents most drugs from reaching the tumor in adequate concentrations. The tumor’s location in critical brain structures also makes surgical removal impossible in nearly all cases.
Newer Treatment Approaches
A compound called ONC201 has shown the most promising results in recent years. In two clinical trials involving 71 patients with H3 K27M-mutated DMGs, those who started treatment before their tumor recurred had a median overall survival of nearly 22 months, roughly double what previous patients achieved. Almost a third of those patients lived longer than two years. While not a cure, this represents a meaningful shift for a disease where survival has been measured in months for decades.
Researchers are also testing ways to physically bypass the blood-brain barrier. One approach called convection-enhanced delivery uses a small pump implanted under the skin of the abdomen, connected to a thin tube placed directly into the tumor. In a phase I trial of nine pediatric patients, this system delivered a cancer drug directly into the pons, achieving coverage of about 80% of the tumor on the first infusion. The treatment was well tolerated with no drug-related toxicity limits reached, and median overall survival was 16.5 months from diagnosis.
CAR-T cell therapy, which engineers a patient’s own immune cells to attack tumor cells, is being studied for DMG as well. Early trials target a molecule called GD2 found on the surface of these tumor cells. Results from these trials are still maturing, but the approach represents a fundamentally different strategy from radiation and drug-based treatments.
Prognosis and What to Expect
DMG remains one of the most difficult cancers to treat. For children with DIPG, the historical median survival has been approximately 9 to 11 months from diagnosis, with fewer than 10% surviving two years. Adult patients generally follow a similar trajectory, though individual outcomes vary depending on tumor location, molecular subtype, and response to treatment.
Thalamic DMGs are uncommon, representing only 1 to 5% of pediatric brain tumors, and their behavior can differ somewhat from pontine tumors. Spinal cord DMGs are rarer still. Across all locations, the grade 4 classification reflects the aggressive nature of these tumors and the current limits of available treatment. The progress with ONC201 and direct-delivery techniques offers cautious reason for hope, but the disease continues to carry a very serious prognosis.